Squamous cell lung cancer (SCL) is a major subtype of non-small cell lung cancer characterized by malignant cells that arise from the squamous epithelial layer of the lung tissue. This type of cancer is often associated with the negative effects of tobacco smoking and can develop in the main bronchi as well as in smaller airways. SCL stands out from other forms of lung cancer due to its aggressive nature, tendency to metastasize, and poor prognosis, especially in the later stages. SCL diagnosis and treatment involve combinations of surgery, chemotherapy, and radiation, which requires a comprehensive approach to therapy.
History of the disease and interesting historical facts
Squamous cell lung cancer was first described in medical literature at the beginning of the 20th century. One of the first doctors to address this pathology was Hans Salmon, who described the morphological features of this form of cancer in 1934. Since then, the number of clinical studies aimed at studying the etiology and pathogenesis of SCL has increased significantly. In the 1960s and 1970s, with increasing awareness of the dangers of smoking, the number of studies devoted to the relationship between smoking and the development of squamous cell lung cancer increased.
Epidemiology
According to the World Health Organization, squamous cell lung cancer accounts for about 25-30% of all cases of non-small cell lung cancer. According to statistics, more than 2 million cases of this disease are registered annually in the world, with the highest incidence observed in countries with high smoking rates. In 2020, over 70 thousand new cases of lung cancer were registered in Russia, of which about 25% were squamous cell cancer. In men, this disease occurs 2-3 times more often than in women, which is due to the high level of smoking among the male population.
Genetic predisposition to this disease
Studies show that people with squamous cell lung cancer may have certain genetic mutations and polymorphisms that increase the likelihood of developing the disease. In particular, the TP53 and EGFR genes stand out among the genes involved. Mutations in the TP53 gene, which is responsible for programmed cell death, can lead to cell cycle dysregulation and excessive cell division. Genes that control the pharmacokinetics of tobacco smoke may also affect susceptibility to squamous cell lung cancer. Diagnosis of mutations and polymorphisms may become an important aspect of individualized therapy.
Risk factors for the development of this disease
The main risk factors that contribute to the development of squamous cell lung cancer are:
- Tobacco smoking is associated with an increased risk of almost all types of lung cancer, including squamous cell carcinoma.
- Second-hand smoke - exposure to tobacco smoke also increases the risk of disease in non-smokers.
- Working in polluted environments - inhalation of chemical carcinogens such as asbestos, arsenic, chromium and nickel.
- Chronic lung diseases, AHD and chronic obstructive pulmonary diseases.
- Age - The risk increases with age, especially after age 50.
- Heredity - a family predisposition to lung cancer.
Diagnosis of this disease
The main symptoms of squamous cell lung cancer may include:
- A persistent cough that may become chronic.
- Hemoptysis, which indicates damage to the blood vessels of the lungs.
- Chest pain associated with tumor growth.
- Shortness of breath and difficulty breathing.
- Loss of weight and appetite.
Laboratory tests include a complete blood count and biopsy to confirm the diagnosis. Radiological tests such as chest X-ray, computed tomography (CT) scan, and positron emission tomography (PET) scan are key to visualizing the tumor and detecting metastases. Other diagnostic tests may include bronchoscopy to obtain tumor tissue samples. Differential diagnosis is important to rule out other lung diseases such as pneumonia or tuberculosis.
Treatment
The main approaches to treating squamous cell lung cancer include:
- Surgical treatment is resection of the tumor and lymph nodes, which can be a radical approach in the early stages of the disease.
- Chemotherapy treatment is traditionally used to systemically target tumor cells.
- Radiation therapy - can be used both for localized forms of the disease and to relieve symptoms at more advanced stages.
- Immunotherapy - opens up new possibilities in treatment by using the body's immune responses against cancer cells.
List of medications used to treat this disease
The main drugs used in the treatment of squamous cell lung cancer include:
- Paclitaxel
- Docetaxel
- Carbat taxel
- Cisplatin
- Gemcitabine
- Erlotinib
- Nivolumab
Disease monitoring
Monitoring of treatment for squamous cell lung cancer involves regular examinations and evaluation of the patient. The prognosis depends on the stage of the disease and the presence of metastases. In the early stages, survival is significantly higher, while later stages often lead to poor outcomes. Complications may include recurrence of the disease, metastasis to other organs, and negative effects from treatment.
Age-related features of the disease
Squamous cell lung cancer is most common in people over 50 years of age. In older patients, the disease may manifest itself with more rapidly progressing symptoms and requires special attention in the choice of treatment methods. In young people suffering from squamous cell lung cancer, the disease may be associated with genetic disorders and a more aggressive course.
Questions and Answers
- What are the main symptoms of squamous cell lung cancer? The main symptoms include cough, hemoptysis, chest pain and shortness of breath.
- How is squamous cell lung cancer diagnosed? Diagnosis includes radiography, CT scan, bronchoscopy and biopsy.
- What are the main risk factors? Major risk factors include smoking, passive smoking, and having chronic lung disease.
- What is the treatment for squamous cell lung cancer? Treatment may include surgery, chemotherapy, and radiation therapy.
- What is the chance of survival if diagnosed with squamous cell lung cancer? The prognosis depends on the stage of the disease; in the early stages, survival is higher, but as the disease progresses, the probability decreases.
